Ocumetics Announces Appointment of President and CEO

Ocumetics Announces Appointment of President and CEO

(TheNewswire)

Ocumetics Technology Corp.

Dean Burns, a 27-year Alcon Vision veteran, will lead Ocumetics through the clinical trial and commercialization process

Calgary, Alberta TheNewswire - June 12 2023 - Ocumetics Technology Corp. (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) (" Ocumetics " or the " Corporation ") is pleased to announce that it has appointed Mr. Dean Burns as Ocumetics' President and CEO.  Mr. Burns will also join the Ocumetics board of directors.  Mr. Burns was previously a consultant of the Corporation, assisting with the Corporation's regulatory and marketing endeavours. Further to the announcement of Dr. Mark Lee's resignation effective June 30, 2023, Dr. Lee stepped down as President and CEO on June 12, 2023.

"We are pleased to have Dean move from a consulting capacity to join our team on a full-time basis in a leadership role," said Dr. Garth Webb, Chairman of the Board of Ocumetics.  "Dean will draw on his 27 years of experience navigating the regulatory process and product commercialization with Alcon Vision to lead Ocumetics as we commence clinical trials," added Dr. Webb.

Mr. Burns is recently retired from Alcon Vision, where he was a Senior Director of Cataract Instrumentation and Advanced Consumable Technology, a US$750 million business of Alcon.  At Alcon, Mr. Burns managed technologies in four therapeutic categories: Cataract, Refractive, Retinal and Pharmaceutical. Mr. Burns' 27-year career with Alcon brings a diverse healthcare experience to Ocumetics.  His experience included developing plans to commercialize acquired technologies and line extension of existing products. He also has skills and experience in marketing and sales management, manufacturing, comprehensive understanding of the regulatory process for devices, Key Opinion Leader management, and surgeon clinical training.  Mr. Burns' accomplishments include over 15 FDA product approvals and five business development and licensing acquisition projects totaling US$2.3 billion.

"I am thrilled to join Ocumetics on a full-time basis," said Dean Burns.  "Over the past year, in my consulting capacity, I have seen first-hand the market potential of the Ocumetics lens technology.  The potential for this technology is incredible and I look forward to leading the process to bring it to market.  My 90-day priorities include meeting with shareholders, engaging new investors and raising capital to fund our Phase 1 clinical trials."

In conjunction with his appointment, Ocumetics has issued 1,600,000 incentive stock options to Mr. Burns.  Each option entitles the holder to purchase one common share of Ocumetics at an exercise price per common share of $0.32 for a period of five years.  The options will vest over three years, with 15% of the options vesting six months after the date of issuance, another 15% vesting after 12 months, another 15% after 18 months, another 15% after 24 months, another 20% after 30 months and the remaining 20% after 36 months.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and development company that specializes in adaptive intraocular lens designs. Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an expandable intraocular lens that fits within the capsular bag following extracapsular cataract extraction.  It is designed to allow the eyes natural muscle activity to shift focus from distance to near, potentially to eliminate the need for corrective lenses.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns, President and CEO

(817) 874-7564

Dayton Marks, Director

(778) 347-2500

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Copyright (c) 2023 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

OTC:CA
The Conversation (0)
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta May 24, 2024 - TheNewswire .  Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

(TheNewswire)

Calgary, Alberta TheNewswire - May 15, 2024. Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to $4,000,000 (the " Principal "). The debentures will be subject to an original issue discount of 6%, resulting in net available funds to the Corporation of up to $3,760,000 (the " Net Proceeds "). Debentures will bear interest at rate of 18% per annum, compounded annually. The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue. The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Technology Corp  To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

Ocumetics Technology Corp To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - February 29, 2024 - Ocumetics Technology Corp. ("Ocumetics") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Announces Extension of Private Placement

Ocumetics Announces Extension of Private Placement

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta TheNewswire - December 21, 2023 -  Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that the TSX Venture Exchange has granted a 15-day extension to close the Corporation's non-brokered private placement announced on November 15, 2023.  The new closing deadline for the private placement is January 15, 2024.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

(TheNewswire)

Ocumetics Technology Corp.

Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less
Nutritional Growth Solutions Limited

Binding Commitments Received for A$1.0 Million under Convertible Note Placement

Nutritional Growth Solutions Limited (ASX:NGS) ("NGS" or "the Company"), is pleased to announce that it has received binding commitments for the issue of 1,000,000 convertible notes (Placement CNs), to be issued at $1.00 each (CN Placement).

Keep reading...Show less

Latest Press Releases

Related News

Ă—